Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
5/17/2012 11:36:22 AM
WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC). ArQule announced that this randomized, double-blind study met its primary endpoint in January and will now present the full results from this trial, including positive data in the pre-defined c-MET high population. Additional clinical data with tivantinib will be featured in two poster discussions and two general poster sessions. Abstracts of these presentations with tivantinib have been published on www.asco.org.